Results 131 to 140 of about 205,939 (352)
Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. [PDF]
, 2019 The increasing number of patients with sequenced prostate cancer genomes enables us to study not only individual oncogenic mutations, but also capture the global burden of genomic alterations.
Bose, Rohit, Ryan, Matthew J
core +1 more source
Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma
Head &Neck, EarlyView.ABSTRACT Purpose Olfactory neuroblastoma (ONB) is a rare sinonasal malignancy with limited therapeutic options in the recurrent/metastatic setting; little is known regarding its responsiveness to immunotherapy. Inhibition of enhancer of zeste homolog 2 (EZH2) has been shown to improve T‐cell‐mediated killing and susceptibility to immune checkpoint ...
Elisabetta Xue +12 more
wiley +1 more source
Quality of Life After Surgical Treatment of Head and Neck Paragangliomas
Head &Neck, EarlyView.ABSTRACT Background Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors and often arise in the head and neck. Due to their localization, the tumor and its surgical treatment pose a risk for cranial nerve impairments. Few studies have focused on the health‐related quality of life (HRQOL) in patients with HNPGLs and their relation to ...
Christina Sauter +5 more
wiley +1 more source
Molecular imprinting for neurology: Materials, applications, and limitations
Ibrain, EarlyView.Molecularly imprinted materials: diagnostic, therapeutic and research applications in neurology. Molecularly imprinted materials offer high specificity and affinity for target molecules in neurological applications. This review highlights their synthesis, characterisation, and use in diagnostics, research and therapeutics.
Xiaohan Ma +3 more
wiley +1 more source
A novel therapeutic strategy for pancreatic neoplasia using a novel RNAi platform targeting PDX-1 [PDF]
, 2011 Bi-functional shRNA (bi-shRNA), a novel RNA interference (RNAi) effector platform targeting PDX-1 utilizing a systemic DOTAP-Cholesterol delivery vehicle, was studied in three mouse models of progressive pancreatic neoplasia.
Charles Brunicardi +13 more
core +1 more source
Primary neuroendocrine tumor of breast: Diagnosing and treating a rare case [PDF]
, 2019 Poorva Vias +4 more
openalex +1 more source
Survival outcomes and prognostic factors of gastric carcinoma with neuroendocrine differentiation
International Journal of Cancer, EarlyView.What's New? Although gastric carcinoma with neuroendocrine differentiation (GCNED) is associated with more aggressive features than conventional GC, its prognosis and survival remain poorly defined. To better understand survival patterns, the authors of the present study examined clinicopathological and prognostic features of GCNED patients following ...
Jinjin Li +7 more
wiley +1 more source
iLABMED, EarlyView.We identified FOXA2 as a key regulator of lymph node metastasis in thyroid cancer, which controls cancer cell aggressiveness. FOXA2 knockdown promotes metastasis by enhancing tumor cell migration and, importantly, by inducing T‐cell apoptosis through a CCL2/LCN2‐mediated pathway. Created with BioGDP.com.
Ping Yang +6 more
wiley +1 more source
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. [PDF]
, 2019 Cancer cell lines are a cornerstone of cancer research but previous studies have shown that not all cell lines are equal in their ability to model primary tumors.
Aran, D +9 more
core +1 more source